Company Overview

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company focused on the development, manufacture, and commercialization of plasma-derived biologics for the treatment and prevention of infectious diseases and immune deficiencies. The company operates within the specialty biologics and plasma therapeutics industries, with its primary focus on immune globulin products derived from human plasma. ADMA’s core revenue drivers are its commercial immune globulin therapies and plasma collection operations, which support both internal manufacturing needs and external plasma sales. The company primarily serves hospitals, specialty pharmacies, infusion centers, physicians, and patients with compromised immune systems in the United States.

ADMA’s commercial portfolio includes products such as BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies used for primary humoral immunodeficiency and related immune conditions. The company also operates a vertically integrated business model through its plasma collection subsidiary network, providing greater control over raw material supply and manufacturing economics. ADMA was founded in 2004 and evolved from a development-stage biotechnology company into a fully integrated commercial biologics manufacturer following acquisitions of manufacturing and plasma collection assets, including the acquisition of the Boca Raton manufacturing facility previously owned by Biotest Pharmaceuticals.

Business Operations

ADMA generates revenue through two primary operational areas: its Commercial Products business and its Plasma Collection Centers network. The company manufactures and markets plasma-derived biologics including BIVIGAM, ASCENIV, and previously Nabi-HB, while also operating FDA-licensed plasma collection facilities under the ADMA BioCenters brand. Plasma collected through these centers supports ADMA’s internal production requirements and contributes to supply chain stability for its immune globulin products. Manufacturing operations are centered at the company’s FDA-approved biologics manufacturing facility in Boca Raton, Florida.

The company’s operations are primarily domestic, with the majority of revenue generated in the United States healthcare market. ADMA controls significant portions of its manufacturing and plasma sourcing infrastructure, which differentiates it from smaller biotechnology firms that rely heavily on third-party manufacturers. The company has also maintained commercial and supply relationships with healthcare distributors, specialty pharmacy channels, and plasma industry participants. Its operational strategy emphasizes vertical integration, manufacturing capacity expansion, and improved plasma yield efficiency.

Strategic Position & Investments

ADMA’s strategic direction has focused on expanding production capacity, increasing plasma collection throughput, and optimizing yields from its proprietary manufacturing processes. The company has invested substantially in manufacturing enhancements at its Boca Raton facility, including process improvements intended to increase IVIG output and operational efficiency. Management has consistently identified supply security and scale as key competitive priorities within the plasma-derived therapeutics market.

The company’s acquisition of manufacturing and plasma collection assets from Biotest Pharmaceuticals significantly altered its long-term strategy by enabling commercial-scale production and vertical integration. ADMA has also invested in expanding its ADMA BioCenters footprint to secure plasma supply in a market characterized by constrained raw material availability. In addition to commercial expansion, the company has explored specialty immunoglobulin applications and process technologies designed to improve antibody-rich plasma fractionation and product differentiation within the immunology sector.

Geographic Footprint

ADMA’s headquarters are located in Ramsey, New Jersey, while its principal manufacturing operations are based in Boca Raton, Florida. The company operates plasma collection centers across multiple U.S. states through the ADMA BioCenters network. Its commercial activities are concentrated primarily within the United States, where its products are distributed through specialty healthcare channels and institutional customers.

Although ADMA’s operational footprint is predominantly domestic, the company participates in a globally interconnected plasma therapeutics industry involving international plasma supply dynamics, biologics regulation, and manufacturing standards. Its production infrastructure and FDA-licensed facilities position the company within the broader global plasma-derived biologics market, though public filings indicate the majority of direct commercial operations remain U.S.-focused.

Leadership & Governance

ADMA’s leadership team has emphasized vertical integration, manufacturing scalability, plasma supply security, and disciplined commercial execution as central elements of the company’s long-term strategy. Public company governance is overseen by a board of directors and executive leadership team with backgrounds in biotechnology, plasma therapeutics, pharmaceuticals, manufacturing, and healthcare operations.

Key executives include:

• Adam S. Grossman – President and Chief Executive Officer
• Brian Lenz – Executive Vice President and Chief Financial Officer
• Jerrold B. Grossman, M.D. – Chief Medical and Scientific Officer
• Tom Silberg – Chief Operating Officer
• Steve Elms – Senior Vice President, Plasma Services

Information presented above is consistent with publicly available disclosures including SEC filings, company investor materials, and major financial reporting sources. Where operational details vary between reporting periods, the most consistently reported and verifiable information has been used.